Please describe what you see up there.
What about below, as the full scene appears? [Read more…] about Quick brain teaser: What do you see? And, can you unsee it?
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring this time nine scientific reports and industry developments to help promote lifelong brain and mental health.
“… venting likely doesn’t soothe anger as much as augment it. That’s because encouraging people to act out their anger makes them relive it in their bodies, strengthening the neural pathways for anger and making it easier to get angry the next time around. Studies on venting anger (without effective feedback), whether online or verbally, have also found it to be generally unhelpful … To get out of that, you can ask the person to step back and help you reframe your experience by asking, “How should I think about this differently?” or “What should I do in this situation?”
“The new company would find it pushing well beyond its current mindfulness focus to, “provide the full spectrum of proven, effective virtual support – from mindfulness and meditation, to text-based behavioral health coaching, to video-based therapy and psychiatry – for all types of patient populations.”
12 good tips for students and everyone else
Their independent review concludes that “given the lack of evidence of a robust and meaningful clinical benefit and the known safety signal, we recommend against offering this agent to patients with Alzheimer’s dementia (mild or otherwise) or mild cognitive impairment.”
A strong call to “learn how this regulatory failure occurred and to ensure that it doesn’t occur again”
Addressing the ongoing controversy about conservatorships, a USC Professor of Law, Psychology, and Psychiatry shares a great article to debunk these all-too-common myths
If you have not encountered the “Linda brain teaser” before, please give it a try! If you have, you’ll enjoy the new paper titled Tversky and Kahneman’s Cognitive Illusions: Who Can Solve Them, and Why?
Fascinating approach to gait training.
Neuralink vs. Paradromics vs. non-invasive platforms — quite a stimulating space to track
Wishing you and yours a happy and healthy back-to-school and month of September,
The SharpBrains Team
A fascinating new study, Tversky and Kahneman’s Cognitive Illusions: Who Can Solve Them, and Why?, probes into the cognitive “heuristics and biases” researched by Daniel Kahneman and Amos Tversky since the late 1960s.
If you have never encountered the “Linda brain teaser” before, please give it a try:
Linda is 31 years old, single, outspoken, and very bright. She majored in philosophy. As a student, she was deeply concerned with issues of discrimination and social justice, and also participated in anti-nuclear demonstrations.
Which statement is more probable?
(a) Linda is a bank teller.
(b) Linda is a bank teller and is active in the feminist movement.
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring nine scientific reports and industry developments to help promote lifelong brain health.
#1. A must-read, and must-practice: Promote brain plasticity and keep your mind at ease by taking your daily “exercise pill”
#2. If cognitive stimulation came in a pill it’d be worth a quadrillion, give or take a few trillions: Study finds that cognitive activity in old age may delay the onset of dementia by 5 years
#3. “A young child with low cognitive control is also more likely to develop anxiety later on in childhood, while one with a higher capacity will be more resilient to stress. Raising cognitive control could both treat anxiety in young children and potentially prevent it from becoming worse over time” — Helping young brains fight off anxiety by training and raising cognitive control
“In a national survey last fall, 36% of adults in the U.S. – including 61% of young adults – reported feeling “serious loneliness” during the pandemic. Statistics like these suggest people would be itching to hit the social scene. But if the idea of making small talk at a crowded happy hour sounds terrifying to you, you’re not alone. Nearly half of Americans reported feeling uneasy about returning to in-person interaction regardless of vaccination status.”
“The stress of the pandemic has made an existing mental health crisis even more alarming. We’re seeing this firsthand in adolescents in classrooms across the country and in adults who are reporting symptoms of anxiety and depression at a rate four times pre-pandemic levels” — Ian Chiu, Managing Director at Owl Ventures
“The study demonstrates for the first time the beneficial neurobehavioral effect of a single NFB session in adult ADHD, and reinforces the notion that Event-related potentials (ERPs) could serve as useful diagnostic/prognostic markers of executive dysfunction.”
“Currently, early diagnosis of high-risk CP offers the opportunity for early intervention at a critical developmental plasticity window. The earlier we intervene, the better the outcome is.”
“Support for mental health has needed improvement for many years in the UK. The pathways for accessing services are convoluted, waiting lists are extensive, and outcomes are poor over the long term … Coming up with new ways to maintain good mental health, in a preventative way, will be as essential as providing tools for acute care and we believe technology has a significant role to play.” — Dr Peter Bloomfield, FCC’s head of Policy and Research
Wishing you a happy and healthy month of August,
The SharpBrains Team
NB: Please remember that, if you’re looking for some fun and varied cognitive exercise, you can always try these 25 Brain Teasers, Puzzles & Games that SharpBrains readers have enjoyed the most.
Welcome to a new edition of SharpBrains’ e‑newsletter, providing this time a summary of the saga around the FDA approval of aducanumab (Aduhelm) as a supposed treatment for Alzheimer’s Disease, plus a range of timely research findings and resources for lifelong brain health.
First, below are some key reads to navigate “probably the worst drug approval decision in recent U.S. history” — Dr. Aaron Kesselheim, the Professor of Medicine at Harvard Medical School who resigned rom the FDA Advisory Committee in protest.
“The Institute for Clinical and Economic Review (ICER) believes that the FDA, in approving aducanumab (Aduhelm by Biogen) for the treatment of Alzheimer’s disease, has failed in its responsibility to protect patients and families from unproven treatments with known harms.”
“The FDA’s approval of Aduhelm raises more questions and creates more problems than a new drug approval should. It’s time for governmental, professional, and advocacy entities to step in where Biogen and the FDA have failed and explain to patients, caregivers, and clinicians how this drug is not the “new day” in the fight against Alzheimer’s disease and needs to be approached cautiously, if at all.” — Dr. Sam Gandy, Professor of Neurology and Psychiatry at the Icahn School of Medicine at Mount Sinai, where he holds the Mount Sinai Chair in Alzheimer’s Research
“In short, while the amyloid hypothesis has faltered, the approval of aducanumab, which is based primarily on this theory, suggests that the theory may once again dominate research, and could reduce the chances of finding more promising treatments. For example, tau protein, which also accumulates in the brains of Alzheimer’s patients — long before the amyloid protein does — has been shown to be closely associated with the cognitive impairment resulting from the disease … we must not interrupt research on biomarkers and new therapeutic approaches.”
#4. US Senator Joe Manchin calls for a new FDA Commissioner to replace current (acting) one who “has repeatedly ignored public health concerns and shown a dereliction of duty” over opioids and aducanumab:
“I write today concerning the lack of permanent leadership at the Food and Drug Administration (FDA), and the continued tenure of Dr. Janet Woodcock as interim commissioner. Just last week, the FDA granted approval for Aduhelm (aducanumab), a treatment for Alzheimer’s, despite its advisory panel voting nearly unanimously against its approval, with no panel member voting in favor of approval”
(Let’s hope something useful emerges from this very unhealthy FDA decision. Quite disturbing, though, to notice the links between the opioid epidemic and the recent Aduhelm approval.)
“Under the broad label that FDA approved, the drug is available to all Alzheimer’s patients, and the agency did not place limits on treatment duration suggesting that patients could remain on the drug indefinitely. We are troubled by reports that those factors could lead the drug to command “somewhere between” the $37 billion we currently spend on Medicare Part B and the $90 billion we currently spend on Medicare Part D. This level of potential new spending, particularly for just one product with limited evidence of clinical efficacy thus far, tests the program’s resiliency.”
The stakes couldn’t be higher.
Now let’s review other important developments in June.
” … big do-it-yourself investing and trading venues like Vanguard Group, Fidelity Investments and Charles Schwab Corp. are strengthening some of the ways they detect possible signs of decline. Among other things, all three firms check for clients’ difficulty navigating security protocols or need for frequent password resets. In such cases, a designated family member might be informed.
Vanguard also checks client-call recordings for keywords—such as “confused” and “dementia”—that might signal trouble.”
“While retirement schemes like the 401(k) and similar programs in other countries are typically introduced to ensure the welfare of aging adults, our research suggests they need to be designed carefully to avoid unintended and significant adverse consequences. When people consider retirement, they should weigh the benefits with the significant downsides of a sudden lack of mental activity. A good way to ameliorate these effects is to stay engaged in social activities and continue to use your brains in the same way you did when you were working.
In short, we show that if you rest, you rust.”
“Digital mental health can be viewed as a way to extend the mental resources that we have,” said David Mohr, who directs the Center for Behavioral Intervention Technologies at the Northwestern University Feinberg School of Medicine. A step-care model, for example, would allow patients with milder symptoms to be treated via technology while reserving in-person care for patients who need something more.
“Pear is one of nine companies invited to participate in the U.S. Food and Drug Administration’s (FDA) Precertification Pilot Program. Pear has developed and commercialized the first three FDA-authorized PDTs, has 14 product candidates, and is scaling its platform for third-party product distribution opportunities. The Company’s three FDA-authorized products, reSET®, reSET‑O® and Somryst®, address large market opportunities with more than 20 million patients suffering from substance and opioid use disorders and more than 30 million from chronic insomnia, in the U.S. alone, respectively.”
“(Research findings) suggest that cognitive function may need to be monitored closely in individuals with affective disorders, as these individuals may be at particular risk of greater cognitive decline.”
#11. Smarter cars are coming soon … : Eye-tracking pioneer Smart Eye acquires MIT spin-off Affectiva to augment driver monitoring systems and more
Finally, a quick cognitive exercise. Given the universal beauty of math, you don’t need to speak Spanish to try this quick teaser: Brain teasers en español: ¿cuál es el número que falta en el cuarto triángulo?
Wishing you a happy and healthy summer,
The SharpBrains Team
(Same brain teaser in English here)
Es viernes y quizás algunos necesitemos un pequeño empujón cognitivo para abordar el fin de semana…
Aquí va un breve desafío matemático: ¿Qué número que falta en el cuarto triángulo?
Aviso a tod@s esos sharp brains: Sí, puede haber más de una respuesta … pero asegúrate de que tu solución funciona bien en todos los triángulos!
[Read more…] about Brain teasers en español: ¿cuál es el número que falta en el cuarto triángulo?